Biosergen
Biosergen publishes interim report for first quarter 2023
REG
Summary of the Interim Report for Q2 2023
| 2023 | 2022 | 2023 | 2022 | 2022 | |
| TSEK | April-June | April-June | Jan-June | Jan-June | Jan-Dec |
| Profit/loss | |||||
| Other income | 2.456 | 1.409 | 7.771 | 2.726 | 5.183 |
| Profit/loss before depreciation (EBITDA | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
| Operating profit/loss befor net financials | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
| Net financials | 7 | 3 | 9 | 6 | 81 |
| Netprofit/loss for the period | -8.031 | -7.960 | -13.058 | -12.975 | -34.048 |
| Earnings per share (SEK) | -0,19 | -0,28 | -0,31 | -0,46 | -1,09 |
Highlights during Q2 2023
- March 29, Biosergen provides Phase 2 clinical development strategy update.
Highlights after the period
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
The Financial report can be found on our website: https://biosergen.net/investors/filings
| Datum | 2023-08-14, kl 08:14 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!